Isogenica Limited

To develop a new to market drug validated in pre-clinical programmes ('virtual cancer patient') aimed at improving cancer immunotherapy.

Recombinant therapeutic proteins and many vaccines are costly to manufacture. Current state-of-the-art protein expression systems include: * Mammalian Chinese Hamster Ovary (CHO) and HEK293 systems. _Limitations:_ Slow-growing cells, expensive media, high energy burden (e.g., for supplying CO2, and for heating the cell cultures), high environmental burden...

The ability to assemble genes from smaller DNA fragments or generate combinatorial libraries of genetic mutations is fundamental to the field of synthetic biology. Different methodologies exist for their fabrication but enzymatic assembly produces a consistently high quality product, compared to other methods, which is essential for downstream processes f...

The E2D2 project will develop and demonstrate novel technologies combined in an integrated approach that identifies active medicinal drugs by exploiting Omics information. By developing technologies to link together the platforms of three UK SMEs, E2D2 will enable an information-led platform approach for drug discovery, delivering novel active drug compou...

The aim of the antibody library construction project is to use a cutting edge technology to create a prototype library of biological drugs that will showcase the approach and enable Isogenica to expand its business into the supply of similar libraries to the pharmaceutical industry. Isogenica has identified this niche in the market through discussions wit...